Celcuity Expenses Jump 81 Percent
Celcuity (NASDAQ:CELC), a clinical-stage biotechnology company developing targeted therapies for cancer, released its second quarter 2025 earnings on August 14, 2025. The highlight was topline Phase 3 data for lead drug gedatolisib, which showed unprecedented results in advanced breast cancer patients. The company posted a non-GAAP EPS loss of ($0.93), wider than the analyst consensus estimate of ($0.88) non-GAAP. Total operating expenses climbed to $44.0 million as development efforts expanded, contributing to a net loss (non-GAAP) that missed expectations. Despite the higher loss, Celcuity showcased strong clinical momentum and increased its cash position with a major capital raise, supporting operations through 2027. The quarter positioned Celcuity at a turning point as it transitions from research to pursuing commercial drug approval.
Source: Analyst estimates for the quarter provided by FactSet.
Celcuity is a clinical-stage biotechnology company focused on discovering and developing targeted therapies for cancer. Its core strategy centers around gedatolisib, an investigational small molecule designed to inhibit multiple cancer-driving enzymes in cell signaling pathways. Gedatolisib targets two major molecular pathways, PI3K and mTOR, which are often implicated in resistance to existing cancer treatments.
Source Fool.com
